Thalamic Neuromodulation: New Frontiers

Area of Science:

• Neurology
• Neurosurgery
• Epileptology

Background:

• Thalamic neuromodulation has advanced from ablative thalamotomy to network-guided deep-brain stimulation (DBS) and responsive neurostimulation (RNS) for drug-resistant epilepsy.
• The anterior thalamic nucleus is the sole FDA-approved DBS target, effective for limbic and temporal epilepsies.
• Emerging evidence implicates centromedian and pulvinar nuclei in generalized and neocortical epilepsies.

Purpose of the Study:

• To review the evolution and current state of thalamic neuromodulation for drug-resistant epilepsy.
• To discuss advanced targeting methods and the role of stereoelectroencephalography in selecting optimal neuromodulation targets.
• To compare the efficacy and safety of different neuromodulation modalities and highlight areas for future research.

Main Methods:

• Review of current literature on thalamic neuromodulation techniques for epilepsy.
• Discussion of advanced imaging, probabilistic atlases, and connectomics for target refinement.
• Analysis of thalamic stereoelectroencephalography data for understanding ictal dynamics and biomarker identification.

Main Results:

• Anterior thalamic nucleus DBS provides significant seizure reduction in specific epilepsy types.
• Centromedian and pulvinar nuclei show promise for other epilepsy classifications.
• Both DBS and RNS have distinct advantages, with no single modality proving superior. Pediatric data show similar safety and efficacy to adults.

Conclusions:

• Thalamic neuromodulation is an evolving treatment for drug-resistant epilepsy.
• Refining neuromodulation targets using advanced techniques and stereoelectroencephalography is crucial.
• Further research is needed to optimize target selection and programming paradigms for improved patient outcomes.